CAS NO: | 51-21-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
200mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
50 g | 电议 |
生物活性 | 5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affectspyrimidine synthesisby inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil inducesapoptosisand can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibitsHIV[3]. | ||||||||||||||||
IC50& Target[1][6] |
| ||||||||||||||||
体外研究 (In Vitro) | 5-Fluorouracil (5-Fu) and NSC 123127 (Dox) show synergistic anticancer efficacy. The IC50value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively[1]. In 5-fluorouracil (5-FU) and CDDP treated NFBD1-inhibited NPC cells, the NFBD1 expression in NPC CNE1 cell lines is depleted using lentivirus-mediated short hairpin RNA, and the sensitivity of these cells is elevated. NFBD1 knockdown leads to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells[2]. | ||||||||||||||||
体内研究 (In Vivo) | 5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 130.08 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C4H3FN2O2 | ||||||||||||||||
CAS 号 | 51-21-8 | ||||||||||||||||
中文名称 | 5-氟脲嘧啶;双喃呋啶 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(384.38 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |